Repository logo
 
Publication

The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy

2020Journal article Restricted access
Simple item page
dc.contributor.authorSantos, PB
dc.contributor.authorLobo, J
dc.contributor.authorFélix, A
dc.contributor.authorSilva, F
dc.contributor.authorManso, RT
dc.contributor.authorCosta, J, et al.
dc.date.accessioned2020-07-02T10:42:00Z
dc.date.available2020-07-02T10:42:00Z
dc.date.issued2020
dc.description.abstractINTRODUCTION: The influence of inflammation on prostate tumor carcinogenesis is currently much better known than with its role in prostate cancer (CaP) progression. We evaluated the prognostic value of epigenetic (HDAC1, HDAC4, H3Ac) and inflammation-related (CXCR4, CXCR7, CXCL12) biomarkers immunoexpression, in radical prostatectomy specimens, from 2 cohorts of CaP patients with long term follow-up. MATERIALS AND METHODS: Formalin-fixed and paraffin-embedded radical prostatectomy specimens were obtained from the pathology archives of Prof. Doutor Fernando Fonseca Hospital, in Amadora, Portugal and Portuguese Oncology Institute of Porto, in Porto, Portugal, and tissue microarrays were assembled. It was achieved a set of 234 patients submitted to radical retropubic prostatectomy between January 2000 and December 2005. Immunohistochemistry was used for evaluation of protein expression of epigenetic and inflammation-related markers. Nuclear staining was assessed using digital image analysis. Study outcomes included disease-specific survival and disease-free survival (DFS). Statistical analysis was tabulated using SPSS version 23.0. Hazard ratios (HRs) and survival curves were estimated using Cox-regression and Kaplan-Meyer models, respectively. Statistical significance was set at P < 0.05. RESULTS: Complete follow-up data was available for 234 patients and median follow-up time was 164 [11-218] months. Patients with higher CXCR4 immunoexpression experienced significantly worse disease-specific survival compared to patients with low expression (HR = 1.016, 95% CI: 1.002-1.031). The same happened with CXCL12 (HR = 0.546 95% CI: 0.322-0.926) and H3Ac (HR = 1.015, 95% CI: 1.001c1.029). In what concerns to DFS, patients with higher expression of CXCR4 and CXCR7 were significantly more prone to experience disease recurrence (HR = 1.003, 95% CI: 1.000-1.005 and HR = 1.111, 95% CI:1.032-1.196, respectively). When adjusted to pTStage and WHO Grade Groups, CXCR7 maintained independent impact on DFS (HR = 1.119, 95% CI: 1.032-1.214). CONCLUSIONS: The interplay between inflammation and epigenetics and its impact in CaP outcome deserves further studies in the future. CXCR7 shows an independent predictor for worse DFS after radical prostatectomy, and could provide important prognostic information for patient management after radical prostatectomy.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationUrol Oncol. 2020 Apr 8. pii: S1078-1439(20)30088-0pt_PT
dc.identifier.doi10.1016/j.urolonc.2020.03.004pt_PT
dc.identifier.issn1873-2496
dc.identifier.urihttp://hdl.handle.net/10400.10/2438
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.subjectProstatic neoplasmspt_PT
dc.subjectProstatectomypt_PT
dc.subjectTumor biomarkerspt_PT
dc.subjectHospital Prof. Dr. Fernando Fonseca, E.P.E.pt_PT
dc.subjectPortugalpt_PT
dc.titleThe inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlacePhiladelphia, PApt_PT
oaire.citation.titleUrologic Oncology: Seminars and Original Investigationspt_PT
rcaap.rightsclosedAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Urol Oncol. 2020.pdf
Size:
3.13 MB
Format:
Adobe Portable Document Format
Download

Collections

URO - Artigos publicados em revistas indexadas
ANPAT - Artigos publicados em revistas indexadas